StocksMediumUpdated•Originally published 9 November 2026•Updated 9 November 2026•
1 min read
Praxis Precision Medicines Beats EPS Estimates with $1.3B Cash Position
Key Facts
1Praxis reported cash and investments of approximately $1.3 billion as of September 30, 2026, providing a runway into 2028.
2Topline results from the EMERALD study of relutrigine are expected in Q4 2026, with a PDUFA target action date of December 27, 2026.
3The FDA has set a PDUFA target action date of January 29, 2027, for the review of ulixacaltamide HCI.
Praxis Precision Medicines reported a Non-GAAP loss per share of $3.23, beating analyst estimates by $0.40. According to a company statement via GlobeNewswire, the firm held cash and investments of approximately $1.3 billion as of September 30, 2026, providing an operational runway into 2028.
The company is awaiting topline results from the EMERALD study of relutrigine expected in the fourth quarter of 2026, while the FDA has set a December 27, 2026, deadline for a regulatory decision on the asset. PRAX closed at $277.62 on November 6, 2026, having traded between a low of $260.77 and a high of $278.98 during that session.